An open label, single arm IIT clinical study evaluating the safety, tolerability, and preliminary efficacy of GCB-001 in the treatment of patients with delayed onset type 2 SMA who can sit alone but cannot walk
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs GCB 001 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Therapeutic Use
- Acronyms GITOPWTSMA
- Sponsors Genecombio
- 20 Jan 2025 New trial record
- 10 Jan 2025 Recruitment completion is expected on 31 Dec 2025, according to Chinese Clinical Trial Register.